Cannabis is not an effective treatment for common mental health conditions, says review
A recent review confirms cannabis not effective mental health treatment for anxiety, depression, and PTSD. Clinical trials show lack of efficacy, highlighting risks of delaying proven therapies. Patients and clinicians should prioritize evidence-based…
Are Hemp-Derived Drinks Here To Stay? – Beverage Information Group
Hemp-derived beverage regulations are evolving rapidly, impacting clinical counseling and patient safety. Understanding the 10 mg THC limit per serving is crucial for clinicians. These regulations address dosing, labeling, and potential drug interactions…
VA Sets January 2027 for Adult-Use Cannabis Sales: Last Week in Weed March 9–16, 2026
Virginia adult-use cannabis sales are scheduled to start in January 2027, marking a key regulatory milestone. This change will provide a regulated market that clinicians can reference for patient counseling. The new framework aims to improve product…
Tennessee Regulators Find Over 650 Unlicensed Hemp Cannabinoid Sellers
Tennessee regulators have found more than 650 unlicensed hemp cannabinoid product sellers operating in the state. This unregulated market poses significant safety risks due to unknown potency and contaminants. Clinicians should be aware of these…
Medical Cannabis May Do More Harm Than Good to Mental Health
Medical cannabis mental health risks are increasingly recognized in clinical research. Evidence suggests medicinal cannabis may worsen outcomes in vulnerable psychiatric patients. Clinicians should carefully assess and monitor mental health when…
Recent Cannabis Research Digest: 20 Studies – March 16, 2026
This recent cannabis research digest presents 20 peer-reviewed studies curated for clinical relevance and evidence quality. The digest covers diverse topics including cannabis use in endometriosis, rheumatology, and adolescent mental health. Stay…
Legacy Cannabis Brand Announces Nationwide Product Expansion
The legacy cannabis brand announces a nationwide expansion of cannabinol sleep aid products. Clinical evidence for cannabinol sleep aid remains limited, requiring careful monitoring. Patients increasingly seek these products as alternatives to…
Court Grants Dismissal of THC Potency Action – Law360 Analysis
The court's dismissal of cannabis THC potency limits challenges leaves regulatory authority with state agencies. Clinicians must counsel patients on high potency cannabis risks. Understanding cannabis THC potency limits is essential for safe clinical…
FDA Submits New Cannabis Products Enforcement Policy For White House Review
The FDA cannabis enforcement policy marks a key regulatory step for the evolving cannabis marketplace. This policy aims to standardize product labeling and safety documentation. Clinicians should monitor this policy for clearer guidance on cannabis…
Pa. Senate Amends Cannabis Bill with Stricter Pennsylvania Hemp Standards
Pennsylvania hemp standards have been updated to align with stricter federal regulations, enhancing cannabis product safety. These changes reduce contamination risks and improve product consistency for medical cannabis users. Clinicians can now counsel…